Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate
Actinobacillus pleuropneumoniae (APP) is a significant pathogen in the swine industry, leading to substantial economic losses and highlighting the need for effective vaccines. This study evaluates the potential of APP-derived extracellular vesicles (APP-EVs) as a vaccine candidate compared to the co...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Virulence |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21505594.2025.2453818 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593516296929280 |
|---|---|
| author | Su Hyun Park Yun Hye Kim Hyeon Jin Lee Jeong Moo Han Byoung-Joo Seo Gyeong-Seo Park Chonghan Kim Young Bae Ryu Woo Sik Kim |
| author_facet | Su Hyun Park Yun Hye Kim Hyeon Jin Lee Jeong Moo Han Byoung-Joo Seo Gyeong-Seo Park Chonghan Kim Young Bae Ryu Woo Sik Kim |
| author_sort | Su Hyun Park |
| collection | DOAJ |
| description | Actinobacillus pleuropneumoniae (APP) is a significant pathogen in the swine industry, leading to substantial economic losses and highlighting the need for effective vaccines. This study evaluates the potential of APP-derived extracellular vesicles (APP-EVs) as a vaccine candidate compared to the commercial Coglapix vaccine. APP-EVs, isolated using tangential flow filtration (TFF) and cushioned ultracentrifugation, exhibited an average size of 105 nm and a zeta potential of −17.4 mV. These EVs demonstrated stability under external stressors, such as pH changes and enzymatic exposure and were found to contain 86 major metabolites. Additionally, APP-EVs induced dendritic cell (DC) maturation in a Toll-like receptor 4 (TLR4)-dependent manner without cytotoxicity. APP-EVs predominantly elicited Th1-mediated IgG responses in immunized mice without significant liver and kidney toxicity. Contrarily, unlike Coglapix, which induced stronger Th2-mediated responses and notable toxicity. In addition, APP-EVs triggered APP-specific Th1, Th17, and cytotoxic T lymphocyte (CTL) responses and promoted the activation of multifunctional T-cells. Notably, APP-EV immunization enhanced macrophage phagocytosis and improved survival rates in mice challenged with APP infection compared to those treated with Coglapix. These findings suggest that APP-EVs are promising vaccine candidates, capable of inducing potent APP-specific T-cell responses, particularly Th1, Th17, CTL, and multifunctional T-cells, thereby enhancing the protective immune response against APP infection. |
| format | Article |
| id | doaj-art-010aa1ecf0614b83b8684ba8d1577276 |
| institution | Kabale University |
| issn | 2150-5594 2150-5608 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Virulence |
| spelling | doaj-art-010aa1ecf0614b83b8684ba8d15772762025-01-20T11:25:16ZengTaylor & Francis GroupVirulence2150-55942150-56082025-12-0116110.1080/21505594.2025.2453818Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidateSu Hyun Park0Yun Hye Kim1Hyeon Jin Lee2Jeong Moo Han3Byoung-Joo Seo4Gyeong-Seo Park5Chonghan Kim6Young Bae Ryu7Woo Sik Kim8Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, KoreaFunctional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of KoreaFunctional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of KoreaVaccine Lab, WOOGENE B&G Co. LTD, Seoul, Republic of KoreaVaccine Lab, WOOGENE B&G Co. LTD, Seoul, Republic of KoreaVaccine Lab, WOOGENE B&G Co. LTD, Seoul, Republic of KoreaFunctional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of KoreaFunctional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of KoreaActinobacillus pleuropneumoniae (APP) is a significant pathogen in the swine industry, leading to substantial economic losses and highlighting the need for effective vaccines. This study evaluates the potential of APP-derived extracellular vesicles (APP-EVs) as a vaccine candidate compared to the commercial Coglapix vaccine. APP-EVs, isolated using tangential flow filtration (TFF) and cushioned ultracentrifugation, exhibited an average size of 105 nm and a zeta potential of −17.4 mV. These EVs demonstrated stability under external stressors, such as pH changes and enzymatic exposure and were found to contain 86 major metabolites. Additionally, APP-EVs induced dendritic cell (DC) maturation in a Toll-like receptor 4 (TLR4)-dependent manner without cytotoxicity. APP-EVs predominantly elicited Th1-mediated IgG responses in immunized mice without significant liver and kidney toxicity. Contrarily, unlike Coglapix, which induced stronger Th2-mediated responses and notable toxicity. In addition, APP-EVs triggered APP-specific Th1, Th17, and cytotoxic T lymphocyte (CTL) responses and promoted the activation of multifunctional T-cells. Notably, APP-EV immunization enhanced macrophage phagocytosis and improved survival rates in mice challenged with APP infection compared to those treated with Coglapix. These findings suggest that APP-EVs are promising vaccine candidates, capable of inducing potent APP-specific T-cell responses, particularly Th1, Th17, CTL, and multifunctional T-cells, thereby enhancing the protective immune response against APP infection.https://www.tandfonline.com/doi/10.1080/21505594.2025.2453818Actinobacillus pleuropneumoniaeextracellular vesicleimmunogenicityTh1-dominant cellullar immunityTh1-dominant humoral immunitypre-exposure vaccine |
| spellingShingle | Su Hyun Park Yun Hye Kim Hyeon Jin Lee Jeong Moo Han Byoung-Joo Seo Gyeong-Seo Park Chonghan Kim Young Bae Ryu Woo Sik Kim Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate Virulence Actinobacillus pleuropneumoniae extracellular vesicle immunogenicity Th1-dominant cellullar immunity Th1-dominant humoral immunity pre-exposure vaccine |
| title | Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate |
| title_full | Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate |
| title_fullStr | Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate |
| title_full_unstemmed | Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate |
| title_short | Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate |
| title_sort | immunogenicity and vaccine efficacy of actinobacillus pleuropneumoniae derived extracellular vesicles as a novel vaccine candidate |
| topic | Actinobacillus pleuropneumoniae extracellular vesicle immunogenicity Th1-dominant cellullar immunity Th1-dominant humoral immunity pre-exposure vaccine |
| url | https://www.tandfonline.com/doi/10.1080/21505594.2025.2453818 |
| work_keys_str_mv | AT suhyunpark immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT yunhyekim immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT hyeonjinlee immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT jeongmoohan immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT byoungjooseo immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT gyeongseopark immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT chonghankim immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT youngbaeryu immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate AT woosikkim immunogenicityandvaccineefficacyofactinobacilluspleuropneumoniaederivedextracellularvesiclesasanovelvaccinecandidate |